Journal
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Volume 19, Issue 1, Pages E9-E11Publisher
CIG MEDIA GROUP, LP
DOI: 10.1016/j.clml.2018.10.002
Keywords
CD38 antibodies; CMV; Infectious complication; Plasma cell dyscrasia; Viral infection
Categories
Ask authors/readers for more resources
We report a case of symptomatic cytomegalovirus (CMV) reactivation upon initiation of daratumumab monotherapy treatment in a heavily pretreated patient with multiple myeloma (MM). In patients with MM, the risk of CMV reactivation is increased following autologous stem cell transplantation. Limited data is available on the incidence of CMV reactivation in patients with MM who did not receive a stem cell transplantation. To our knowledge, this is the first report of a symptomatic CMV reactivation during daratumumab monotherapy treatment. Although routine monitoring for CMV is not recommended, the possibility of a CMV reactivation should be considered in patients with MM treated with daratumumab and infectious symptoms that cannot otherwise be explained. (C) 2018 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available